Table 4 Univariate analysis of parameters for the prediction of survival outcomes in 164 non-metastatic ccRCC patients

Gender

0.61(0.30–1.26)

0.181

1.19(0.27–5.31)

0.824

Age

1.18(1.08–1.30)

 < 0.001

1.06(0.99–1.14)

0.085

Smoking

0.90(0.44–1.84)

0.768

1.56(0.35–6.99)

0.561

Drinking

0.73(0.33–1.64)

0.449

0.04(0.00–304.09)

0.476

Hypertension

0.82(0.41–1.64)

0.576

9.35(1.12–77.75)

0.039

DM

0.85(0.30–2.43)

0.765

1.82(0.22–15.11)

0.581

Anemia

0.16(0.03–0.81)

0.027

5.26(1.02–27.11)

0.047

Renal dysfunction

2.89(0.36–23.51)

0.321

0.05(0.00–1.06E)

0.723

ALT

0.99(0.94–1.04)

0.584

0.99(0.95–1.04)

0.727

AST

0.98(0.90–1.07)

0.657

0.90(0.77–1.05)

0.170

BUN

1.12(0.97–1.29)

0.132

1.10(0.91–1.33)

0.310

Tumor number

0.05(0.00–14,033,642.09)

0.760

0.05(0.00–2.67E)

0.767

Tumor size

13.33(3.33–53.35)

 < 0.001

17.39(3.89–77.75)

 < 0.001

PMP score (2 + 3/0 + 1)

0.07(0.01–0.34)

0.001

0.08(0.02–0.40)

0.002

T stage

(III + IV/ I + II)

15.61(3.87–62.91)

 < 0.001

20.80(4.63–93.38)

 < 0.001

Grade (III + IV/I + II)

100.78(12.37–820.98)

 < 0.001

100.91(12.05–845.06)

 < 0.001

Tumor hemorrhage

0.05(0.00–9123.80)

0.618

0.04(0.00–15,007.24)

0.632

Tumor necrosis

0.05(0.00–420,311.62)

0.708

0.05(0.00–1.99E)

0.733

Lymphatic and microvascular infiltration

3.49(0.43–28.40)

0.242

9.76(1.89–50.32)

0.006